World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
33912
World Ranking
11234
National Ranking
5768

Overview

Beverly A. Teicher is affiliated with the National Institutes of Health in the United States and has a broad research portfolio primarily spanning medicine and biochemistry, genetics, and molecular biology.

Their published work includes significant contributions to the fields of oncology and cancer research, with a notable focus on molecular biology, pulmonary and respiratory medicine, and neurology. The scientist's research areas extend into subfields such as molecular biology, oncology, cancer research, pulmonary and respiratory medicine, and neurology.

Main topics addressed in their research include:

  • Cancer Genomics and Diagnostics
  • Neuroblastoma Research and Treatments
  • CAR-T Cell Therapy Research
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Research Studies
  • Lung Cancer Treatments and Mutations
  • Sarcoma Diagnosis and Treatment

Frequent co-authors working alongside Beverly A. Teicher include James H. Doroshow, Malcolm A. Smith, Nathan P. Coussens, Thomas S. Dexheimer, and Stephen W. Erickson.

Beverly A. Teicher has contributed to several well-known publication venues, including:

  • Cancer Research
  • Molecular Cancer Therapeutics
  • Pediatric Blood & Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research Communications

Recent notable publications include:

  • "Cancer treatments: Past, present, and future," 2024, published in Cancer Genetics
  • "SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures," 2020, published in Cell Reports
  • "The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models," 2021, Clinical Cancer Research
  • "TGFβ-Directed Therapeutics: 2020," 2020, Pharmacology & Therapeutics
  • "Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets," 2020, Clinical Epigenetics

Best Publications

  • CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

    Beverly A. Teicher;Simon P. Fricker

  • Overexpression of metallothionein confers resistance to anticancer drugs.

    Susan L. Kelley;Alakananda Basu;Beverly A. Teicher;Miles P. Hacker

  • Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

    Junko Murai;Shar-yin N. Huang;Amèlie Renaud;Yiping Zhang

  • Classification of Antineoplastic Agents by their Selective Toxicities toward Oxygenated and Hypoxic Tumor Cells

    Beverly A. Teicher;John S. Lazo;Alan C. Sartorelli

  • Hypoxia and drug resistance

    Beverly A. Teicher

  • Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β

    Victoria C. Liu;Larry Y. Wong;Thomas Jang;Ali H. Shah

  • The proteasome inhibitor PS-341 in cancer therapy.

    Beverly A. Teicher;Gulshan Ara;Roy Herbst;Vito J. Palombella

  • Antibody-drug conjugates for cancer therapy.

    Anish Thomas;Beverly A Teicher;Raffit Hassan

  • A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

    K Antman;L Ayash;A Elias;C Wheeler

  • Antibody conjugate therapeutics: challenges and potential.

    Beverly A. Teicher;Ravi V.J. Chari

  • Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.

    Beverly A. Teicher;Terence S. Herman;Sylvia A. Holden;Yenyun Wang

  • The hypoxic tumor cell: a target for selective cancer chemotherapy.

    Katherine A. Kennedy;Beverly A. Teicher;Sara Rockwell;Alan C. Sartorelli

  • Acquired multicellular-mediated resistance to alkylating agents in cancer.

    Hiroaki Kobayashi;Shan Man;Charles H. Graham;Sean J. Kapitain

  • Characterization of a Human Squamous Carcinoma Cell Line Resistant to cis-Diamminedichloroplatinum(II)

    Beverly A. Teicher;Sylvia A. Holden;Michael J. Kelley;Thomas C. Shea

  • Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.

    Beverly A. Teicher;Sylvia A. Holden;Gulshan Ara;Enrique Alvarez Sotomayor

  • Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.

    Beverly A. Teicher;Enrique Alvarez Sotomayor;Zhen Dong Huang

  • Comprehensive characterization of the Published Kinase Inhibitor Set

    Jonathan M. Elkins;Vita Fedele;Marta Szklarz;Kamal R. Abdul Azeez

  • Perfluorochemical emulsions can increase tumor radiosensitivity

    Beverly A. Teicher;Christopher M. Rose

  • PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

    Benjamin H. Lok;Eric E. Gardner;Eric E. Gardner;Valentina E. Schneeberger;Andy Ni

  • Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.

    Beverly A. Teicher;Sylvia A. Holden;Antoine Al-Achi;Terence S. Herman

Frequent Co-Authors

Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
James H. Doroshow
James H. Doroshow National Institutes of Health
Peter J. Houghton
Peter J. Houghton The University of Texas Health Science Center at San Antonio
Richard Gorlick
Richard Gorlick The University of Texas MD Anderson Cancer Center
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Yves Pommier
Yves Pommier National Institutes of Health
Paul S. Meltzer
Paul S. Meltzer National Institutes of Health
Yael P. Mosse
Yael P. Mosse Children's Hospital of Philadelphia
Katherine W. Klinger
Katherine W. Klinger Sanofi (United States)
William C. Reinhold
William C. Reinhold National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending a traditional, on-campus program. Today, more students are taking advantage of flexible options such as cheapest online fnp program pathways, which allow aspiring nurse practitioners to earn credentials affordably and conveniently.

For those just beginning their journey, nursing school online opens doors to entry-level and advanced nursing roles while balancing other life commitments. Registered nurses seeking advancement can benefit from cheap rn to bsn online programs that deliver quality instruction without the high cost or need to relocate.

Professionals interested in research or academic positions can consider pursuing an online phd in nursing, which provides the flexibility to conduct research and further knowledge while managing work responsibilities.

These affordable online degree choices broaden access to rewarding healthcare careers, supporting students at every stage—whether starting out, advancing, or specializing within the field of medicine.

Best Scientists Citing Beverly A. Teicher

Trending Scientists

Recently Published Articles